Andrew Slee
Chief Operating Officer chez PROTAGENIC THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Andrew Slee is currently the Chief Operating Officer at Protagenic Therapeutics, Inc. He previously held positions as Senior Director-Preclinical Pharmacology at Safety Pharmacology Society, Principal at DuPont Pharmaceuticals Co. and DuPont Merck Pharmaceutical Co., and Vice President-Pharmacology at Enanta Pharmaceuticals, Inc. He also served as Vice President-Pharmacology & Development at SelectX Pharmaceuticals, Inc. from 2000 to 2012.
Dr. Slee received his undergraduate degree from Syracuse University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 26/03/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Andrew Slee
| Sociétés | Poste | Début |
|---|---|---|
| PROTAGENIC THERAPEUTICS, INC. | Chief Operating Officer | 01/02/2016 |
Anciens postes connus de Andrew Slee
| Sociétés | Poste | Fin |
|---|---|---|
SelectX Pharmaceuticals, Inc.
 SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
| ENANTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a private company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Corporate Officer/Principal | - |
DuPont Pharmaceuticals Co.
 DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Corporate Officer/Principal | - |
| Safety Pharmacology Society | Corporate Officer/Principal | - |
Formation de Andrew Slee
| Syracuse University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| PROTAGENIC THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
DuPont Pharmaceuticals Co.
DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a private company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
SelectX Pharmaceuticals, Inc.
SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Health Technology |
| Safety Pharmacology Society |
